Halozyme Therapeutics (HALO) Capital Expenditures (QoQ) (2010 - 2026)
Halozyme Therapeutics (HALO) Capital Expenditures (QoQ) (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Halozyme Therapeutics | 9.55 Bn | 9.23 Bn | 297.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 162.16% |
| Dec 31, 2025 | -52.90% |
| Sep 30, 2025 | 93.86% |
| Jun 30, 2025 | 64.53% |
| Mar 31, 2025 | 112.90% |
| Dec 31, 2024 | -203.05% |
| Sep 30, 2024 | 334.53% |
| Jun 30, 2024 | -185.95% |
| Mar 31, 2024 | -75.98% |
| Dec 31, 2023 | 12,199.18% |
| Sep 30, 2023 | -146.04% |
| Jun 30, 2023 | -32.05% |
| Mar 31, 2023 | -83.36% |
| Dec 31, 2022 | 132.54% |
| Sep 30, 2022 | -12.27% |
| Jun 30, 2022 | 271.84% |
| Mar 31, 2022 | 125.18% |
| Dec 31, 2021 | -347.38% |
| Sep 30, 2021 | -6.94% |
| Jun 30, 2021 | 97.41% |